Literature DB >> 24445913

Prostate cancer: How to manage prostate cancer with lymph node metastases?

Günter Janetschek1, Stephan Hruby1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24445913     DOI： 10.1038/nrurol.2013.321

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  5 in total

1.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.

Authors:  John F Ward; Jeffrey M Slezak; Michael L Blute; Erik J Bergstralh; Horst Zincke
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

2.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.

Authors:  A W Partin; M W Kattan; E N Subong; P C Walsh; K J Wojno; J E Oesterling; P T Scardino; J D Pearson
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

3.  Laparoscopic radioisotope-guided sentinel lymph node dissection in staging of prostate cancer.

Authors:  Stephan Jeschke; Avi Beri; Martin Grüll; Josef Ziegerhofer; Peter Prammer; Karl Leeb; Wolfgang Sega; Guenter Janetschek
Journal:  Eur Urol       Date:  2007-03-28       Impact factor: 20.096

4.  Predicting survival of patients with node-positive prostate cancer following multimodal treatment.

Authors:  Firas Abdollah; R Jeffrey Karnes; Nazareno Suardi; Cesare Cozzarini; Giorgio Gandaglia; Nicola Fossati; Marco Bianchi; Stephen A Boorjian; Maxine Sun; Pierre I Karakiewicz; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2013-09-27       Impact factor: 20.096

5.  Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.

Authors:  Alberto Briganti; Jeffrey R Karnes; Luigi Filippo Da Pozzo; Cesare Cozzarini; Andrea Gallina; Nazareno Suardi; Marco Bianchi; Massimo Freschi; Claudio Doglioni; Ferruccio Fazio; Patrizio Rigatti; Francesco Montorsi; Michael L Blute
Journal:  Eur Urol       Date:  2008-10-01       Impact factor: 20.096
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.